What could stop the decision?

Test whether a sourcing opportunity deserves more work. Identify the evidence, cost assumptions and practical risks that could change the decision.

Question
Define the decision
Support
Trace original sources
Limit
Show conflicts and unanswered questions
Action
Test before commitment
Method structure · not a live feed or supplier rating
Public recordsPublished sourcesSupplier claimsOpen gapsINTERPRETATIONSource lineageNext check
PUBLIC EVIDENCE

What is visible?

Published market and company records support a market. They do not establish a buyer-specific award decision.

Method illustration · no live feed or supplier rating

Visibility is not verification.

The finding carries its sources, disagreements and remaining checks into the commercial decision.

Source lineage / method illustration
01Original record
02Definition + date
03Claim tested
04Contradiction / gap
05Decision implication

Repetition is not independent corroboration. How well a claim is supported and our confidence remain separate.

Most commercial opportunities look strongest before the difficult questions are asked.

A market may be growing, but inaccessible to the buyer. A supplier route may be technically possible, but dependent on one fragile input. A lower-cost sourcing option may require compliance work that removes the economic advantage. A new market may be attractive in theory but too small, slow or concentrated to justify execution.

PhaseVane tests feasibility before the buyer commits too far.

The output is not a generic risk register.

It is a decision view:

What has to be true for this decision to work? Which conditions are supported? Which are weak? What could stop execution? What should be tested next?

“Possible” is not the same as commercially viable.

A product can technically be manufactured in a market and still be a poor sourcing decision.

A market can contain customers and still be too small to justify entry.

A supplier can pass a desk review and still lack the capacity required for the buyer’s forecast.

Feasibility should therefore be expressed as a set of conditions.

Example:

This sourcing route is viable if three suppliers can meet certification, MOQ remains below the buyer’s threshold and landed cost stays within the required range.

Now the research has something concrete to test.

Every commercial decision contains assumptions.

Typical assumptions include:

  • enough suppliers exist;
  • certification is obtainable;
  • landed economics remain attractive;
  • logistics are workable;
  • tariffs do not erase the advantage;
  • the market is large enough;
  • capacity is available;
  • the buyer can implement within the required time.

PhaseVane makes those assumptions explicit.

The analysis then asks:

Which assumptions are supported, which are weak and which are currently unknown?

  1. 01

    Decision Question

    Bound the commercial choice.

  2. 02

    Evidence

    Keep sources and states attached.

  3. 03

    Contradiction

    Record what does not agree.

  4. 04

    Confidence / Gaps

    Expose the limit of the finding.

  5. 05

    Commercial Implication

    Show what changes for the buyer.

  6. 06

    Action

    Proceed, test, hold or investigate.

Supplier count is only one layer of resilience.

Supply risk can come from:

  • too few credible suppliers;
  • one industrial cluster;
  • one upstream source;
  • constrained capacity;
  • long replenishment;
  • weak quality systems;
  • regulatory dependency;
  • logistics concentration.

The research should distinguish visible alternatives from genuinely independent alternatives.

The economics can fail even when the supply route works.

Commercial feasibility can be undermined by:

  • MOQ;
  • payment;
  • tooling;
  • low annual volume;
  • freight;
  • duty;
  • FX;
  • inventory;
  • switching cost.

A low supplier quote can hide a weak business case.

The correct unit of analysis is the buyer’s decision, not the factory price alone.

Compliance can be a gating condition.

A market opportunity can disappear if:

  • required certification is unavailable;
  • testing cost is disproportionate;
  • approval takes too long;
  • labeling or documentation creates barriers;
  • rules of origin fail;
  • import restrictions apply.

PhaseVane should classify compliance as:

  • known;
  • likely;
  • unresolved;
  • blocking.

The analysis should not substitute for legal advice, but it should identify where specialist validation is required.

A viable strategy can still fail in implementation.

Execution risk includes:

  • insufficient internal capacity;
  • qualification timing;
  • supplier responsiveness;
  • unclear ownership;
  • data gaps;
  • stakeholder delay;
  • logistics setup;
  • contract/approval cycles.

A report that ignores implementation can recommend a theoretically attractive route that the buyer cannot execute.

Diversification should be measured at the dependency level.

Five suppliers do not create five independent options if:

  • they share one upstream component;
  • use one port;
  • rely on one industrial zone;
  • depend on one certification body;
  • use the same subcontractor.

PhaseVane should identify the dependency that matters to the buyer rather than counting supplier names.

  1. 01

    Decision Question

    Bound the commercial choice.

  2. 02

    Evidence

    Keep sources and states attached.

  3. 03

    Contradiction

    Record what does not agree.

  4. 04

    Confidence / Gaps

    Expose the limit of the finding.

  5. 05

    Commercial Implication

    Show what changes for the buyer.

  6. 06

    Action

    Proceed, test, hold or investigate.

A good opportunity can still be wrong now.

Commercial feasibility changes with time.

A new plant may be two years from meaningful production.

A tariff preference may not yet apply.

A compliance change may be pending.

A supplier market may be developing but not mature enough for the buyer’s current schedule.

PhaseVane should distinguish:

  • viable now;
  • viable after a defined event;
  • potentially viable;
  • not yet supported.

Feasibility improves when contradictions are surfaced early.

Example:

Market evidence: strong.

Supplier evidence: shallow.

Economics: attractive.

Compliance: unresolved.

The correct conclusion is not “high potential.”

It may be:

HOLD, attractive economics are not enough until compliance feasibility is confirmed.

That is a more useful decision state.

Not every risk deserves equal attention.

A useful risk assessment should consider:

  • likelihood;
  • consequence;
  • reversibility;
  • cost to test.

The most important uncertainty is often not the largest possible risk.

It is the uncertainty that could change the decision and can be resolved cheaply.

Example:

A buyer may spend weeks modelling freight scenarios while the real decision hinges on whether any supplier can meet one required certification.

PhaseVane should prioritise the evidence that matters most.

Possible outputs:

  • PROCEED, material conditions supported.
  • NARROW, viable, but only in a smaller scope/geography/category.
  • HOLD, one or more gating conditions unresolved.
  • TEST ONE ASSUMPTION, decision hinges on a specific unknown.
  • INVESTIGATE NEXT, evidence supports continued research, not execution.

These states should help management allocate the next unit of time or money.

A buyer is evaluating a second-source market.

Evidence:

  • supplier universe appears sufficient;
  • initial quotes are competitive;
  • trade activity is established.

Risks:

  • most suppliers depend on one imported component;
  • destination certification evidence is weak;
  • lead time is longer than the incumbent market.

PhaseVane conclusion:

TEST ONE ASSUMPTION. Before launching full qualification, confirm certification feasibility for two shortlisted suppliers. If the requirement cannot be met without disproportionate cost or delay, the apparent price advantage is commercially irrelevant.

This saves the buyer from investing in the wrong next step.

Depending on scope:

  • decision condition map;
  • risk/feasibility evidence;
  • critical dependencies;
  • regulatory/compliance issues;
  • economic constraints;
  • timing/execution risks;
  • contradiction register;
  • confidence/gaps;
  • priority evidence tests;
  • bounded decision state;
  • next action.

What decision needs a defensible answer?